What is pharmaceutical competitive intelligence?
The scope, the deliverables, who consumes them, and the distinction between intelligence and a pile of collected documents.
Articles
Methods, sources and practice
Reference material on pharmaceutical competitive intelligence — how the work is actually done, where it goes wrong, and what separates a functioning CI team from a well-organised reading list.
Why oncology CI is a different job
Oncology competitive intelligence has to be tracked at indication, line-of-therapy and biomarker level. Here is why tumour-type tracking fails and what the granular version requires.
Congress intelligence: the abstract-to-podium cycle
How pharma CI teams cover oncology congresses: the abstract release and embargo cycle, why presented data differs from the abstract, late-breakers, and what to prepare before you arrive.
Primary vs secondary intelligence
The difference between secondary and primary competitive intelligence in pharma, what each source type can and cannot answer, and how to combine them without paying for interviews you did not need.
Pre-launch competitive intelligence
What competitive intelligence has to deliver in the two years before a pharmaceutical launch: competitor launch sequencing, anticipated labels, access starting conditions, and the differentiation that actually survives to day one.
CI for business development and licensing
How competitive intelligence supports pharmaceutical in-licensing and acquisition diligence: defining the comparator set, forecasting standard of care at launch rather than today, reading the seller's framing, and working inside a banker's timetable.
LOE and biosimilar intelligence
How CI teams track generic and biosimilar entry: the signals available under Hatch-Waxman versus the BPCIA, why biosimilar erosion behaves nothing like generic erosion, and what actually drives the shape of the curve.
CI tools and databases
A practical guide to the pharmaceutical competitive intelligence software and data market: what each category of subscription is genuinely good at, the four questions no database can answer, and how to run an overlap audit before renewal.
The registry is a primary source — if you read the changes
How pharma CI teams actually use ClinicalTrials.gov: which record fields carry competitive signal, why the change history matters more than the record itself, and a monitoring workflow that holds up.
What a CI report actually contains
The structure of a pharmaceutical competitive intelligence report: the five deliverable types, a section-by-section anatomy, sensible cadence, and why most CI documents fail as data dumps.
Automation in CI: an honest division of labour
Which parts of pharmaceutical competitive intelligence automate well — registry diffs, abstract triage, alert routing — which parts do not, and how to use LLMs without outsourcing judgement.